Ewa Zarzycka
Overview
Explore the profile of Ewa Zarzycka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozcan M, Cassaday R, Zarzycka E, Vandendries E, Zhang F, Chen Y, et al.
Haematologica
. 2025 Jan;
PMID: 39882642
Inotuzumab ozogamicin (InO) is approved for treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Previous studies reported higher rates of post- hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome...
2.
Short N, Wierzbowska A, Cluzeau T, Laribi K, Recher C, Czyz J, et al.
Leuk Lymphoma
. 2024 Nov;
66(3):458-468.
PMID: 39606906
Trial Registration: NCT04266795.
3.
Karasek M, Armatys A, Skarupski M, Bolkun L, Budziszewska K, Drozd-Sokolowska J, et al.
Front Oncol
. 2024 Jun;
14:1395992.
PMID: 38835383
Introduction: Mixed-phenotype acute leukemia (MPAL) is a rare disease with poor prognosis. So far, no standard approach has been established as the "know-how" of MPAL is based only on retrospective...
4.
Beldzinska-Gadek K, Zarzycka E, Pastuszak K, Borman K, Lewandowski K, Zaucha J, et al.
Leuk Lymphoma
. 2024 May;
65(9):1292-1302.
PMID: 38775354
Acute leukemia (AL) with a lineage switch (LS) is associated with poor prognosis. The predisposing factors of LS are unknown, apart from rearrangements that have been reported to be associated...
5.
Prejzner W, Piekos O, Beldzinska K, Sadowska-Klasa A, Zarzycka E, Bieniaszewska M, et al.
Front Oncol
. 2023 Nov;
13:1228481.
PMID: 37941558
Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are...
6.
Tyczynska A, Turski M, Zarzycka E, Zaucha J
Biomedicines
. 2023 May;
11(4).
PMID: 37189843
Multiple myeloma (MM) is a disease caused by the uncontrolled proliferation of clonal plasma cells in bone marrow. Extramedullary plasma cell infiltrations may occur at the time of diagnosis but...
7.
Cezary Czarnogorski M, Sakowska J, Maziewski M, Zielinski M, Piekarska A, Obuchowski I, et al.
Immun Ageing
. 2022 Nov;
19(1):51.
PMID: 36324179
Background: Ageing is a complex phenomenon that leads to decreased proliferative activity, loss of function of the cells, and cellular senescence. Senescence of the immune system exacerbates individual's immune response,...
8.
Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al.
N Engl J Med
. 2022 Apr;
386(16):1519-1531.
PMID: 35443108
Background: The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly...
9.
Lewicka E, Daniluk P, Lasocka Z, Zarzycka E, Dabrowska-Kugacka A, Nabialek-Trojanowska I, et al.
Kardiol Pol
. 2020 Mar;
78(5):454-457.
PMID: 32210217
No abstract available.
10.
Sobas M, Czyz A, Montesinos P, Armatys A, Helbig G, Holowiecka A, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Dec;
20(2):105-113.
PMID: 31874794
Background: Acute promyelocytic leukemia (APL) has a favorable prognosis. However, results of randomized studies do not necessarily reflect the outcomes of a real-life population. Patients And Methods: We analyzed 283...